Histamine News and Research RSS Feed - Histamine News and Research

Histamine is a biogenic amine chemical involved in local immune responses as well as regulating physiological function in the gut and acting as a neurotransmitter.
Sleep medicine and research: an interview with James K. Walsh

Sleep medicine and research: an interview with James K. Walsh

There are a variety of sleep medicines. I am going to refer to what are commonly described as hypnotics or sleeping pills. Sleeping pills have been around for a long time. [More]
Tips to help minimize risks associated with acid reflux disease

Tips to help minimize risks associated with acid reflux disease

While the overall death rates from several cancers such as breast and lung have gone down, there has been a meteoric rise in cases of esophageal cancer. Studies have shown that from 1975 to 2001, the incidence of esophageal adenocarcinoma rose approximately sixfold in the United States (from four to 23 cases per million), a relative increase greater than that for melanoma, breast, or prostate cancer. [More]
Grunenthal to commercialize Horizon Pharma's DUEXIS in Latin America

Grunenthal to commercialize Horizon Pharma's DUEXIS in Latin America

Horizon Pharma, Inc. a biopharmaceutical company developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases, today announced that it entered into an exclusive agreement with Grunenthal for the commercialization of DUEXIS in Latin America. [More]
Mallinckrodt, Horizon enter co-promotion agreement for DUEXIS

Mallinckrodt, Horizon enter co-promotion agreement for DUEXIS

Mallinckrodt, the Pharmaceuticals business of Covidien, today announced that it has entered into a co-promotion agreement with Horizon Pharma, Inc. to promote DUEXIS (ibuprofen and famotidine). [More]

Ocera’s Zysa receives CE Mark to treat IBS-d

Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary agents to treat gastrointestinal and liver diseases, announced today that it has received a CE Mark for Zysa (spherical carbon adsorbent, formerly AST-120) for the treatment of diarrhea predominant IBS (IBS-d), a condition affecting 10-15% of the Western world. [More]
FDA approves VIVUS’ STENDRA for treatment of erectile dysfunction

FDA approves VIVUS’ STENDRA for treatment of erectile dysfunction

VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STENDRA (avanafil) tablets for the treatment of erectile dysfunction (ED), marking the first new prescription agent approved in nearly a decade for the condition that afflicts as many as 30 million men in the U.S. [More]

Latest AAN/AHS guidelines can help prevent migraine attacks

The latest American Academy of Neurology/American Headache Society Guidelines released this week outline evidence-based and effective treatments that can prevent migraine attacks and lessen their severity. [More]
Preventive treatments can reduce migraine attacks

Preventive treatments can reduce migraine attacks

Research shows that many treatments can help prevent migraine in certain people, yet few people with migraine who are candidates for these preventive treatments actually use them, according to new guidelines issued by the American Academy of Neurology. [More]

Migraine prevention guidelines released

The latest migraine prevention guidelines will be presented at the American Academy of Neurology's annual meeting in New Orleans and published simultaneously in the journal Neurology. [More]
Risk of botulism at California fish processing company

Risk of botulism at California fish processing company

The U.S. Food and Drug Administration, in a complaint filed by the Department of Justice, is seeking to stop the processing and distribution of fish products at a California company because of a risk of botulism and other food hazards. [More]
Gedeon Richter and Forest Labs' cariprazine Phase III trials on schizophrenia meet primary endpoint

Gedeon Richter and Forest Labs' cariprazine Phase III trials on schizophrenia meet primary endpoint

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced positive top-line results in 2 Phase III clinical trials of cariprazine (RGH-188) for the treatment of acute exacerbation of schizophrenia. [More]

DC-SIGN molecule appears to play a role in fighting allergy

Scientists at The University of Nottingham have discovered a new molecule that could offer the hope of new treatments for people allergic to the house dust mite. [More]
Acid reducing drugs could raise risk of C. diff diarrhea

Acid reducing drugs could raise risk of C. diff diarrhea

U.S. health regulators, the Food and Drugs Administration (FDA), have announced that ulcer drugs such as AstraZeneca Plc's blockbuster Nexium could increase the risk of Clostridium difficile-associated diarrhea (CDAD). [More]
Certain strains of P. aeruginosa cause WBCs to produce high levels of histamine

Certain strains of P. aeruginosa cause WBCs to produce high levels of histamine

Could some cases of asthma actually be caused by an allergic reaction to a common environmental bacteria? New research findings published in the Journal of Leukocyte Biology suggests that this idea may not be as far-fetched as it seems. In a research report appearing in the February 2012 print issue, researchers show a link between common environmental bacteria and airway inflammation. [More]
Oxygen Biotherapeutics to commence study to determine efficacy of Dermacyte in relieving Histamine induced pruritus

Oxygen Biotherapeutics to commence study to determine efficacy of Dermacyte in relieving Histamine induced pruritus

Oxygen Biotherapeutics, Inc. has announced that enrollment for the company’s first dermatological study will begin later this month at St. John’s Medical College Hospital in Bangalore, India. The company received formal approval from the hospital’s Ethics Review Board in December. This study is the first of a series of trials scheduled for 2012 to explore the efficacy of Dermacyte to treat a variety of dermatological conditions, such as allergic contact dermatitis, psoriasis and acne. [More]

HRF inhibitors may provide new therapeutic avenue for treatment of asthma and allergies

La Jolla Institute for Allergy & Immunology scientists have identified the histamine releasing factor (HRF) molecule as a promising target for developing new treatments for a number of allergic reactions including asthma. [More]
Experts share latest buzz on allergies to alcohol and tobacco

Experts share latest buzz on allergies to alcohol and tobacco

While the health benefits of drinking wine in moderation continue to make news, for some with allergies even a glass a day may be difficult to swallow. At the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Boston, Nov. 3-8, allergists share the latest buzz on allergies to alcohol and tobacco. [More]

Frozen ground tuna recalled by Osamu Corporation

Osamu Corporation of Gardena, CA is recalling up to 1,800 cases, lot# 7013, of frozen ground tuna because the FDA found decomposition in several samples of the product and also found elevated histamine levels in samples taken from one retail location. [More]
Aspirin desensitization procedure can benefit patients with sinusitis, asthma and AERD

Aspirin desensitization procedure can benefit patients with sinusitis, asthma and AERD

Beth Moore can now keep up with her children. The suburban Philadelphia mother of two had suffered from allergies and chronic sinusitis since her teens. With age her symptoms became more severe, turning into bronchitis and eventually asthma, diminishing her ability to breathe and sapping her of her energy. The only complete relief came from aspirin; and the aspirin desensitization that allowed her to overcome her aspirin allergy and end her decades-long battle with sinusitis. [More]

Researchers identify gene responsible for aggressive, bold behavior in zebrafish

A gene responsible for aggressive and bold behavior has been identified in zebrafish by a team from CNRS/Laboratoire Neurobiologie et Développement. [More]